Andreas Stallmach1, Arndt Steube, Philip Grunert, Michael Hartmann, Lena M Biehl, Maria J G T Vehreschild. 1. Department of Internal Medicine IV (Gastroenterology, Hepatology, Infectious Diseases), Jena University Hospital, Jena, Germany; University Pharmacy, Jena University Hospital, Jena, Germany; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Germany; German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Germany; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Abstract
BACKGROUND: Fecal microbiota transfer (FMT) is increasingly being used in Ger- many, as in other countries, for the treatment of recurrent Clostridioides difficile infection (rCDI). FMT is now being performed both for research and in individual patients outside of clinical trials. No compulsory standards have been established to date for donor screening or for the method of fecal transfer. Given the potential dangers of FMT, this would seem to be urgently necessary. METHODS: This review is based on pertinent literature retrieved by a selective search, including the reports of consensus conferences from Germany and abroad. RESULTS: Because of its high efficacy, FMT is the treatment of choice for rCDI. It is largely free of adverse side effects, even in immune-deficient patients, as long as comprehensive and repeated donor screening has been carried out, with extensive clinical and microbiological testing and with the use of structured questionnaires. The ingestion of frozen, encapsulated microbiota is just as effective as other modes of delivery for the treatment of rCDI. CONCLUSION: Encapsulation of the fecal microbiome (FM) and storage at -20°C is the method of choice, because it can be standardized with the necessary quality controls and it is readily available. Patients with rCDI should undergo FMT by orally ingesting the capsules. There are ongoing research efforts to identify the active e FM. It is not yet clear when the ultimate goal of recombinant production can be achieved.
BACKGROUND:Fecal microbiota transfer (FMT) is increasingly being used in Ger- many, as in other countries, for the treatment of recurrent Clostridioides difficileinfection (rCDI). FMT is now being performed both for research and in individual patients outside of clinical trials. No compulsory standards have been established to date for donor screening or for the method of fecal transfer. Given the potential dangers of FMT, this would seem to be urgently necessary. METHODS: This review is based on pertinent literature retrieved by a selective search, including the reports of consensus conferences from Germany and abroad. RESULTS: Because of its high efficacy, FMT is the treatment of choice for rCDI. It is largely free of adverse side effects, even in immune-deficientpatients, as long as comprehensive and repeated donor screening has been carried out, with extensive clinical and microbiological testing and with the use of structured questionnaires. The ingestion of frozen, encapsulated microbiota is just as effective as other modes of delivery for the treatment of rCDI. CONCLUSION: Encapsulation of the fecal microbiome (FM) and storage at -20°C is the method of choice, because it can be standardized with the necessary quality controls and it is readily available. Patients with rCDI should undergo FMT by orally ingesting the capsules. There are ongoing research efforts to identify the active e FM. It is not yet clear when the ultimate goal of recombinant production can be achieved.
Authors: Christine H Lee; Theodore Steiner; Elaine O Petrof; Marek Smieja; Diane Roscoe; Anouf Nematallah; J Scott Weese; Stephen Collins; Paul Moayyedi; Mark Crowther; Mark J Ropeleski; Padman Jayaratne; David Higgins; Yingfu Li; Neil V Rau; Peter T Kim Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Colleen R Kelly; Alexander Khoruts; Christopher Staley; Michael J Sadowsky; Mortadha Abd; Mustafa Alani; Brianna Bakow; Patrizia Curran; Joyce McKenney; Allison Tisch; Steven E Reinert; Jason T Machan; Lawrence J Brandt Journal: Ann Intern Med Date: 2016-08-23 Impact factor: 25.391
Authors: Michelle T Hecker; Mark E Obrenovich; Jennifer L Cadnum; Annette L Jencson; Alok K Jain; Edith Ho; Curtis J Donskey Journal: Open Forum Infect Dis Date: 2016-05-05 Impact factor: 3.835
Authors: Ilan Youngster; Jasmin Mahabamunuge; Hannah K Systrom; Jenny Sauk; Hamed Khalili; Joanne Levin; Jess L Kaplan; Elizabeth L Hohmann Journal: BMC Med Date: 2016-09-09 Impact factor: 8.775
Authors: T Schiereck; S Yeldan; J Kranz; L Schneidewind; F Wagenlehner; I Wieters; M J G T Vehreschild; T Otto; D Barski Journal: Urologe A Date: 2021-08-23 Impact factor: 0.639
Authors: Andreas Stallmach; Philip Grunert; Johannes Stallhofer; Bettina Löffler; Michael Baier; Jürgen Rödel; Michael Kiehntopf; Sophie Neugebauer; Dietmar H Pieper; Howard Junca; Andrea Tannapfel; Ute Merkel; Ulrike Schumacher; Maria Breternitz-Gruhne; Tabitha Heller; Anja Schauer; Michael Hartmann; Arndt Steube Journal: Trials Date: 2022-02-22 Impact factor: 2.279
Authors: Nerea M Molina; Alberto Sola-Leyva; Maria Jose Saez-Lara; Julio Plaza-Diaz; Aleksandra Tubić-Pavlović; Barbara Romero; Ana Clavero; Juan Mozas-Moreno; Juan Fontes; Signe Altmäe Journal: Biomolecules Date: 2020-04-11